Systemic chemokine-modulatory regimen combined with neoadjuvant chemotherapy in patients with triple-negative breast cancer
Combined paclitaxel/CKM regimen was safe, with desirable TME changes and preliminary indications of promising pCR+ypTmic of 66%, comparable to the combination of NAC with pembrolizumab.
Authors
- Vladimir Roudko (ORCID: https://orcid.org/0000-0002-3835-6737)
- Kristopher Attwood (ORCID: https://orcid.org/0000-0002-7229-5472)
- Sinem Ozbey (ORCID: https://orcid.org/0000-0001-5636-4709)
- Stephen B. Edge (ORCID: https://orcid.org/0000-0002-3285-6191)
- Kathleen M. Kokolus (ORCID: https://orcid.org/0000-0002-9088-5409)
- Ronald Slomba
- Janine Miller (ORCID: https://orcid.org/0000-0003-1364-7287)
- Tracey L. O’Connor (ORCID: https://orcid.org/0000-0002-9549-7173)
- Suresh Kalathil (ORCID: https://orcid.org/0000-0002-7800-3151)
- Giorgio Ioannou (ORCID: https://orcid.org/0000-0001-7956-7605)
- Jessica Young (ORCID: https://orcid.org/0000-0002-8544-4107)
- Kazuaki Takabe (ORCID: https://orcid.org/0000-0002-6435-4241)
- Paweł Kaliński (ORCID: https://orcid.org/0000-0001-7025-3562)
- Shipra Gandhi (ORCID: https://orcid.org/0000-0003-3506-0284)
- Eduardo Cortes Gomez (ORCID: https://orcid.org/0000-0002-0966-6488)
- Helen Cappuccino
- Sacha Gnjatic (ORCID: https://orcid.org/0000-0001-5643-9520)
- Mateusz Opyrchal (ORCID: https://orcid.org/0000-0003-2454-7441)
- Victoria Fitzpatrick
- Ellis Levine (ORCID: https://orcid.org/0000-0003-2300-0524)
- Jianmin Wang (ORCID: https://orcid.org/0000-0001-8910-0929)
- Prasanna Kumar (ORCID: https://orcid.org/0000-0002-3729-9128)
- Igor De Souza
- Cayla Janes
Institutions
- Indiana University Health (US)
- Roswell Park Comprehensive Cancer Center (US)
- Indiana Cancer Consortium (US)
- Indiana University – Purdue University Indianapolis (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2024-11-01
- DOI
- https://doi.org/10.1136/jitc-2024-010058
- Citations
- 6
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 1.44
Funders
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Roswell Park Alliance Foundation, Roswell Park Cancer Institute
- Celgene
- Regeneron Pharmaceuticals
- National Institutes of Health
- Genentech
- National Cancer Institute
- National Center for Advancing Translational Sciences